Adjacent

Blogs

Q&A with Suchismita Acharya – Founder and CEO of AyuVis Research

  DeciBio’s Women in Consulting group is continuing an initiative to interview women in positions of leadership. As part of this series, I had the opportunity to speak with Suchismita

Q&A with Stephanie Campbell – Co-Founder of the Artemis Fund

  DeciBio’s Women in Consulting group is continuing an initiative to interview women in positions of leadership. In continuation of this series, I had the opportunity to speak with Stephanie

COVID’s Effect on mRNA Assets, Part II: Experience (and Quality) Matters

  With renewed interest in disparate applications and the subsequent flood of newcomers to mRNA asset development, the focus on quality and experience with regard to mRNA is more important

Q&A with Michelle Dipp – Co-Founder and Managing Partner at Biospring Partners

  DeciBio’s Women in Consulting group has started an initiative to interview women in positions of leadership in the life sciences and healthcare industries. As part of this series, I

COVID’s Effect on mRNA Assets, Part I: Vaccines & Delivery

  With a global pandemic to fight, the speed, efficacy, and efficiency of mRNA vaccine research, development, and manufacturing have been proven invaluable. While the Moderna (mRNA-1273) and BioNTech (Comirnaty)

How KKR Made a ~3x Return in 4 Years by Investing in Research Tools

  KKR made headlines late last year with the exit of their investment in LGC Group, a UK-based biochemical standards and reagents provider. Sources say KKR acquired LGC in December

Lessons Learned from the World’s First Gene-Edited Babies

Why enforceable regulation and greater inclusion and diversity in global discourse are critical to effective management of gene editing Earlier this week, He Jiankui, a professor at China’s Southern University

New CRISPR Companies Heat Up as Skepticism Grows

Novel ways of harnessing CRISPR disrupt diagnostics, therapeutics, and food systems While much hype has been built around CRISPR-Cas9 and its ability to revolutionize treatment of genetic disorders and disease,

Think Twice Before Divesting CRISPR Amid Cancer Concerns

Why Headlines Linking CRISPR to Cancer are Misleading Investors Two papers published by Novartis and Karolinska Institute that warn of potential cancer risks associated with CRISPR-Cas9 editing sent share prices